$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000110820517000009 Filed on May 04, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$2.061M	$2.131M	$1.726M
YoY Change	22.68%	23.46%	4.1%
Cost Of Revenue	$100.0K	$110.0K	$90.00K
YoY Change	0.0%	22.22%	-99.63%
Gross Profit	$1.970M	$2.020M	$1.640M
YoY Change	23.9%	23.17%	-107.2%
Gross Profit Margin	95.58%	94.79%	95.02%
Selling, General & Admin	$3.820M	$3.530M	$3.620M
YoY Change	11.05%	-2.49%	2.55%
% of Gross Profit	193.91%	174.75%	220.73%
Research & Development	$11.26M	$13.54M	$6.828M
YoY Change	27.58%	98.32%	44.69%
% of Gross Profit	571.32%	670.35%	416.34%
Depreciation & Amortization	$50.00K	$60.00K	$30.00K
YoY Change	-16.67%	100.0%	-25.0%
% of Gross Profit	2.54%	2.97%	1.83%
Operating Expenses	$11.26M	$13.54M	$6.828M
YoY Change	27.58%	98.32%	44.69%
Operating Profit	-$13.11M	-$15.05M	-$8.807M
YoY Change	22.74%	70.92%	-71.61%
Interest Expense	$1.119M	$656.0K	$740.0K
YoY Change	53.5%	-11.35%	-14.64%
% of Operating Profit
Other Income/Expense, Net	-$981.0K	-$689.0K	-$635.0K
YoY Change	60.82%	8.5%	-23.19%
Pretax Income	-$14.09M	-$15.74M	-$9.440M
YoY Change	24.8%	66.74%	-70.36%
Income Tax
% Of Pretax Income
Net Earnings	-$14.09M	-$15.74M	-$9.441M
YoY Change	24.8%	66.74%	-70.36%
Net Earnings / Revenue	-683.65%	-738.71%	-546.99%
Basic Earnings Per Share
Diluted Earnings Per Share	-$489.9K	-$554.2K	-$365.9K
COMMON SHARES
Basic Shares Outstanding	143.8M shares	141.9M shares	129.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.00M	$60.80M	$73.10M
YoY Change	-17.34%	-16.83%	-26.9%
Cash & Equivalents	$26.68M	$42.42M	$14.69M
Short-Term Investments	$24.40M	$18.40M	$58.40M
Other Short-Term Assets	$1.200M	$1.400M	$900.0K
YoY Change	20.0%	55.56%	12.5%
Inventory
Prepaid Expenses
Receivables	$2.231M	$2.195M	$1.747M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$54.38M	$64.37M	$75.80M
YoY Change	-15.7%	-15.08%	-26.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$426.0K	$410.0K	$383.6K
YoY Change	-5.54%	6.89%	5.38%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.000K	$3.000K	$2.980K
YoY Change	0.0%	0.67%	-95.1%
Total Long-Term Assets	$9.411M	$9.395M	$9.521M
YoY Change	-1.86%	-1.33%	-43.18%
TOTAL ASSETS
Total Short-Term Assets	$54.38M	$64.37M	$75.80M
Total Long-Term Assets	$9.411M	$9.395M	$9.521M
Total Assets	$63.80M	$73.76M	$85.32M
YoY Change	-13.91%	-13.54%	-28.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.202M	$5.905M	$4.870M
YoY Change	111.66%	21.25%	75.03%
Accrued Expenses	$2.480M	$1.573M	$1.519M
YoY Change	23.26%	3.58%	11.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.931M	$3.502M	$5.554M
YoY Change	-27.59%	-36.95%	-0.54%
Total Short-Term Liabilities	$14.61M	$10.98M	$11.94M
YoY Change	29.14%	-8.06%	22.73%
LONG-TERM LIABILITIES
Long-Term Debt	$39.95M	$41.31M	$17.35M
YoY Change	141.57%	138.07%	-20.39%
Other Long-Term Liabilities	$0.00	$0.00	$83.73K
YoY Change	-100.0%	-100.0%	-50.26%
Total Long-Term Liabilities	$39.95M	$41.31M	$17.43M
YoY Change	140.67%	136.93%	-20.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.61M	$10.98M	$11.94M
Total Long-Term Liabilities	$39.95M	$41.31M	$17.43M
Total Liabilities	$54.57M	$52.29M	$29.38M
YoY Change	95.46%	77.98%	-7.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$928.8M	-$914.7M	-$848.0M
YoY Change	8.09%	7.87%	4.51%
Common Stock	$939.5M	$937.7M	$905.4M
YoY Change	3.6%	3.57%	0.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$9.228M	$21.48M	$55.94M
YoY Change
Total Liabilities & Shareholders Equity	$63.80M	$73.76M	$85.32M
YoY Change	-13.91%	-13.54%	-28.49%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$14.09M	-$15.74M	-$9.441M
YoY Change	24.8%	66.74%	-70.36%
Depreciation, Depletion And Amortization	$50.00K	$60.00K	$30.00K
YoY Change	-16.67%	100.0%	-25.0%
Cash From Operating Activities	-$9.220M	-$15.15M	-$7.990M
YoY Change	-15.02%	89.61%	2.96%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	$52.00K	$8.000K
YoY Change	-68.0%	550.0%	-46.51%
Acquisitions
YoY Change
Other Investing Activities	-$5.940M	$70.00K	-$9.280M
YoY Change	-210.61%	-100.75%	-77.13%
Cash From Investing Activities	-$6.010M	$20.00K	-$9.290M
YoY Change	-217.15%	-100.22%	-77.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.214M	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-510.0K	31.51M	-1.120M
YoY Change	59.38%	-2913.39%	-101.75%
NET CHANGE
Cash From Operating Activities	-9.220M	-15.15M	-7.990M
Cash From Investing Activities	-6.010M	20.00K	-9.290M
Cash From Financing Activities	-510.0K	31.51M	-1.120M
Net Change In Cash	-15.74M	16.38M	-18.40M
YoY Change	160.6%	-189.02%	-217.05%
FREE CASH FLOW
Cash From Operating Activities	-$9.220M	-$15.15M	-$7.990M
Capital Expenditures	-$80.00K	$52.00K	$8.000K
Free Cash Flow	-$9.140M	-$15.20M	-$7.998M
YoY Change	-13.77%	90.07%	2.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	cris	Cash Distribution Paidto Parent Company CashDistributionPaidtoParentCompany	26600000	USD
CY2015Q4	cris	Collaborative Arrangement Numberof Optional Additional Terms CollaborativeArrangementNumberofOptionalAdditionalTerms	3	term
CY2015Q4	cris	Collaborative Arrangement Option Fees Numberof Payments CollaborativeArrangementOptionFeesNumberofPayments	2	payment
CY2015	cris	Collaborative Arrangement Option Fees Total CollaborativeArrangementOptionFeesTotal	7500000	USD
CY2015	cris	Collaborative Arrangement Optional Additional Term CollaborativeArrangementOptionalAdditionalTerm	P1Y
CY2016Q1	cris	Employee Benefits Sharebased Compensation Shares Issued Payment Notyet Received EmployeeBenefitsSharebasedCompensationSharesIssuedPaymentNotyetReceived	0	USD
CY2017Q1	cris	Employee Benefits Sharebased Compensation Shares Issued Payment Notyet Received EmployeeBenefitsSharebasedCompensationSharesIssuedPaymentNotyetReceived	174000	USD
CY2017Q1	cris	Numberof Oncology Drug Candidates NumberofOncologyDrugCandidates	2	candidate
CY2017Q1	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2026000	USD
CY2017Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1052000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	928319000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	143772716	shares
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
CY2017Q1	dei	Trading Symbol TradingSymbol	CRIS
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5883000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5905000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2459000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2195000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	16000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	10000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2725000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1573000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	157000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	158000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	936248000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-100000	USD
CY2016Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1455000	USD
CY2017Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	596000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	12000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	119000	USD
CY2016Q4	us-gaap	Assets Assets	57752000	USD
CY2017Q1	us-gaap	Assets Assets	73763000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	48201000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	64368000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18451000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18390000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	18447000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	18385000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33091000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14692000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26038000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42417000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18399000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16379000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	60800000	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142346871	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144900004	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141124025	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143677158	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1423000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	1449000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9410000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15744000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	10533000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	17184000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12500000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M20D
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3616000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3532000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	8982000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	8982000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1148000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-360000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-264000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-243000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-213000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	740000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	656000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	194000	USD
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	112000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	105000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	70000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	28486000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	52286000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57752000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73763000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10980000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13547000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4939000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3502000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14921000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	41306000	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18447000	USD
CY2017Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18385000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1121000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	31507000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-9291000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	18000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7987000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15146000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-9442000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-15742000	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8807000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15053000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	251000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2017Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	103000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-635000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-689000	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	192000	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	29467000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12556000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1257000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1218000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6214000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	70000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	464000	USD
CY2016Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2017Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	45000000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20184000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	12626000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	410000	USD
CY2016Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1191000	USD
CY2017Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1676000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2017Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	18303000	USD
CY2016Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-18000	USD
CY2017Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-60000	USD
CY2016Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6828000	USD
CY2017Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13541000	USD
CY2016Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	0	USD
CY2017Q1	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	153000	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000	USD
CY2017Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-898948000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-914690000	USD
CY2016Q1	us-gaap	Revenues Revenues	1726000	USD
CY2017Q1	us-gaap	Revenues Revenues	2131000	USD
CY2016Q1	us-gaap	Royalty Expense RoyaltyExpense	89000	USD
CY2017Q1	us-gaap	Royalty Expense RoyaltyExpense	111000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1744000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	2191000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	772000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1103000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.64
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.63
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7665796	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.59
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	258003	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5654000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.52
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10598000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13752157	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18699002	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.30
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.37
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.38
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10020000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17557600	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.42
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.10
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.52
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4218000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M25D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M12D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1500000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1500000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	449152	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	29266000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	21477000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129019984	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	142011776	shares
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical stage drug candidates are CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors and CA-170, which is being investigated in a Phase 1 study in patients with advanced solid tumors and lymphomas. The Company’s pipeline includes </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> pre-Investigational New Drug, or IND, stage oncology drug candidates, CA-327 and CA-4948. The Company’s drug Erivedge® (vismodegib) is approved for the treatment of advanced basal cell carcinoma, or BCC. The Company is party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge, a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. In addition to BCC, Roche and Genentech are conducting studies of Erivedge in other diseases, including in idiopathic pulmonary fibrosis and myelofibrosis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, and as amended in September 2016, the Company entered into an exclusive collaboration, option and license agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration with Aurigene is comprised of multiple programs, and Curis has the option to exclusively license each program, including data, intellectual property and compounds associated therewith, once a development candidate is nominated within such program. In October 2015, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration. The first licensed program is in the immuno-oncology field and the Company has named CA-170, an orally-available small molecule antagonist of two immune checkpoints, programmed death ligand-1 (PDL1) and V domain Ig suppressor of T cell activation (VISTA), as the development candidate from this program. CA-170 is currently in Phase 1 clinical testing. The second licensed program is in the precision oncology field and the Company has named CA-4948, an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), as the development candidate. In October 2016, the Company exercised its option to license a third program in the collaboration, and designated CA-327, a distinct orally available small molecule antagonist of two immune checkpoints, PDL1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3), as the development candidate from this program. The Company expects to file IND applications with the United States Food and Drug Administration, or FDA, for clinical testing of CA-4948 and CA-327 in the second half of 2017.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the FDA and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its credit agreement with HealthCare Royalty Partners III, L.P., a Delaware limited partnership managed by Healthcare Royalty Management, LLC, or HealthCare Royalty; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and makes under its current and potential future collaborations. The results of the Company’s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech’s ability to successfully commercialize Erivedge; and positive results in Roche and Genentech’s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred losses and negative cash flows from operations since its inception. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$914.7 million</font><font style="font-family:inherit;font-size:10pt;">. The Company anticipates that its </font><font style="font-family:inherit;font-size:10pt;">$60.8 million</font><font style="font-family:inherit;font-size:10pt;"> of existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> should enable it to maintain its planned operations into 2018. In order to ensure adequate cash resources for 12 months from the issuance date of these financial statements, the Company will reduce or delay spending on its research and development programs and operating expenses to the extent it is unable to raise additional financing through its current </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> at-the-market sale agreement with Cowen and Company, LLC, or Cowen or other potential financing. Accordingly, the inability to obtain additional funds in the next 12 months would have a negative impact on the Company’s financial condition and ability to pursue its business strategies. The Company’s ability to raise additional funds will depend on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company.</font></div></div>

Files In Submission

Name	View Source	Status
0001108205-17-000009-index-headers.html	Edgar Link	pending
0001108205-17-000009-index.html	Edgar Link	pending
0001108205-17-000009.txt	Edgar Link	pending
0001108205-17-000009-xbrl.zip	Edgar Link	pending
cris-20170331.xml	Edgar Link	completed
cris-20170331.xsd	Edgar Link	pending
cris-20170331_cal.xml	Edgar Link	unprocessable
cris-20170331_def.xml	Edgar Link	unprocessable
cris-20170331_lab.xml	Edgar Link	unprocessable
cris-20170331_pre.xml	Edgar Link	unprocessable
cris-3312017x10q1.htm	Edgar Link	pending
cris-3312017x10qexx101.htm	Edgar Link	pending
cris-3312017x10qexx311.htm	Edgar Link	pending
cris-3312017x10qexx312.htm	Edgar Link	pending
cris-3312017x10qexx321.htm	Edgar Link	pending
cris-3312017x10qexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
updatedpipeline33117.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2017 Q2 Form 10-Q Financial Statement

#000110820517000009 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2017 Q2 Form 10-Q Financial Statement

#000110820517000009 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris